Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23841785 | 0.82 | NCF1 (0.40) | NCF1NAMPTDRD2DRD3 | |
| SCHEMBL25658564 | 0.82 | NCF1 (0.40) | NCF1NAMPTDRD2DRD3 | |
| SCHEMBL13713090 | 0.82 | NCF1 (0.40) | NCF1NAMPTDRD2DRD3 | |
| SCHEMBL19098405 | 0.76 | NCF1 (0.35) | NCF1NAMPTDRD2DRD3 | |
| SCHEMBL19098393 | 0.73 | TRPV3 (0.34) | NCF1NAMPTDRD2DRD3 | |
| SCHEMBL23848106 | 0.73 | NCF1 (0.43) | NCF1NAMPT | |
| SCHEMBL20621819 | 0.73 | KCNH2 (0.36) | NCF1DRD3 | |
| SCHEMBL105743 | 0.72 | NCF1 (0.46) | NCF1 | |
| SCHEMBL19098391 | 0.69 | NCF1 (0.39) | NCF1NAMPTDRD2DRD3 | |
| SCHEMBL20666080 | 0.69 | MAPT (0.41) | NAMPTDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | NCF1 1845/4885NAMPT 397/4885DRD2 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.